JP2013500326A - 抗原性タウペプチドおよびその使用 - Google Patents

抗原性タウペプチドおよびその使用 Download PDF

Info

Publication number
JP2013500326A
JP2013500326A JP2012522292A JP2012522292A JP2013500326A JP 2013500326 A JP2013500326 A JP 2013500326A JP 2012522292 A JP2012522292 A JP 2012522292A JP 2012522292 A JP2012522292 A JP 2012522292A JP 2013500326 A JP2013500326 A JP 2013500326A
Authority
JP
Japan
Prior art keywords
peptide
tau
amino acid
seq
antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012522292A
Other languages
English (en)
Japanese (ja)
Inventor
ジョセフ スミス Ｉｉｉ ジョージ
ネルソン ウィルズ ケネス
シャンチャオ チュ ジェフ
Original Assignee
ファイザー バクシーンズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー バクシーンズ エルエルシー filed Critical ファイザー バクシーンズ エルエルシー
Publication of JP2013500326A publication Critical patent/JP2013500326A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012522292A 2009-07-30 2010-07-20 抗原性タウペプチドおよびその使用 Pending JP2013500326A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22986009P 2009-07-30 2009-07-30
US61/229,860 2009-07-30
PCT/IB2010/053313 WO2011013034A1 (en) 2009-07-30 2010-07-20 Antigenic tau peptides and uses thereof

Publications (1)

Publication Number Publication Date
JP2013500326A true JP2013500326A (ja) 2013-01-07

Family

ID=42941871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012522292A Pending JP2013500326A (ja) 2009-07-30 2010-07-20 抗原性タウペプチドおよびその使用

Country Status (17)

Country Link
US (1) US20110177109A1 (enExample)
EP (1) EP2459214A1 (enExample)
JP (1) JP2013500326A (enExample)
KR (2) KR20120049900A (enExample)
CN (1) CN102596236B (enExample)
AR (1) AR078085A1 (enExample)
AU (1) AU2010277254B2 (enExample)
CA (1) CA2768346A1 (enExample)
CO (1) CO6612199A2 (enExample)
IN (1) IN2012DN00446A (enExample)
MX (1) MX2012001194A (enExample)
NZ (2) NZ598356A (enExample)
PE (1) PE20120817A1 (enExample)
RU (2) RU2518291C2 (enExample)
SG (1) SG177637A1 (enExample)
TW (2) TW201436804A (enExample)
WO (1) WO2011013034A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200094761A (ko) * 2017-12-04 2020-08-07 시아먼 이노디엑스 바이오테크 컴퍼니 리미티드 HBsAg의 정량적 검출을 위한 키트 및 방법
JP2021508673A (ja) * 2017-10-27 2021-03-11 ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ タウペプチド免疫原構築物
JPWO2022054795A1 (enExample) * 2020-09-08 2022-03-17
JP2022534406A (ja) * 2019-05-27 2022-07-29 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア タウの立体配座特異的エピトープ、それらに対する抗体、およびそれらに関連する方法

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2481040T3 (es) 2008-12-09 2014-07-29 Coley Pharmaceutical Group, Inc. Oligonucleótidos inmunoestimulantes
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CA3120504A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
BR112013008333B1 (pt) * 2010-10-07 2022-10-11 Ac Immune S.A. Anticorpo, composição farmacêutica, hibridoma, polinucleotídeo, método de diagnóstico in vitro e usos do anticorpo
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
AU2012282678B2 (en) 2011-07-11 2016-03-03 California Institute Of Technology Akt-specific capture agents, compositions, and methods of using and making
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
ES2600915T3 (es) 2011-10-07 2017-02-13 Ac Immune S.A. Anticuerpos fosfoespecíficos que reconocen Tau
WO2013151762A1 (en) 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
KR20150036346A (ko) * 2012-07-03 2015-04-07 워싱턴 유니버시티 Tau에 대한 항체
EA035976B1 (ru) 2012-08-16 2020-09-08 АйПИЕРИАН, ИНК. Анти-tau антитела для лечения таупатий
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
EP3027205A4 (en) * 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
US20180050097A1 (en) * 2015-03-25 2018-02-22 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
US10598671B2 (en) 2015-07-15 2020-03-24 Indi Molecular, Inc. IL-17F-specific capture agents, compositions, and methods of using and making
EP3334453A4 (en) 2015-08-13 2019-02-06 New York University ANTIBODY-BASED SPECIFIC MOLECULES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY, FOR TAU'S SPECIFIC ASP421 EPITOP
EP3519425B1 (en) 2016-09-29 2024-02-28 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
EP3700556A2 (en) * 2017-10-25 2020-09-02 Janssen Pharmaceuticals, Inc. Compositions of phosphorylated tau peptides and uses thereof
CN108314737B (zh) * 2018-01-25 2021-03-16 中国科学院过程工程研究所 一种重组蛋白及其制备方法和应用
CN110548135B (zh) * 2018-05-31 2023-06-06 长春百克生物科技股份公司 磷酸化多肽抗原疫苗及其制备方法和应用
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
JP7719713B2 (ja) 2018-10-07 2025-08-06 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア α－シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法
EA202192203A1 (ru) 2019-02-08 2021-10-20 Ац Иммуне С.А. СПОСОБ БЕЗОПАСНОГО ВВЕДЕНИЯ ВАКЦИНЫ ФОСФОРИЛИРОВАННОГО ПЕПТИДА Tau
EP3921343A4 (en) * 2019-02-08 2022-12-14 Prothena Biosciences Limited ANTIBODIES FOR DETECTING TAU
US20200291391A1 (en) * 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
EP3946605A1 (en) 2019-04-05 2022-02-09 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
JP7617852B2 (ja) 2019-04-24 2025-01-20 ヤンセン ファーマシューティカルズ，インコーポレーテッド タウワクチンの異種投与
WO2020236969A1 (en) 2019-05-20 2020-11-26 Indi Molecular, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
GB2585252A (en) * 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
AU2021321206A1 (en) * 2020-08-07 2023-03-09 Othair Prothena Limited Tau vaccine for the treatment of alzheimer's disease
JP2024534976A (ja) * 2021-09-08 2024-09-26 ジョイント・ストック・カンパニー “バイオキャド” Ｍｈｃタンパク質に基づくヘテロ二量体を含む二重特異性抗体
JP2024538615A (ja) * 2021-09-29 2024-10-23 ヤンセン ファーマシューティカルズ，インコーポレーテッド タウホスホペプチドコンジュゲートの安全な投与の方法
CN115894659B (zh) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050383A1 (en) * 2006-03-29 2008-02-28 New York University Immunotherapy for clearing pathological tau conformers
JP2009132689A (ja) * 2001-01-19 2009-06-18 Cytos Biotechnology Ag 分子抗原アレイ

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
WO1983001451A1 (en) 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
DE3525624A1 (de) 1985-07-18 1987-01-22 Celamerck Gmbh & Co Kg Insektizid wirksames mittel zur bekaempfung von textilschaedlingen
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1993011231A1 (en) * 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
SK117395A3 (en) 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
CA2268825C (en) 1996-10-11 2006-04-18 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ATE252596T1 (de) 1997-06-06 2003-11-15 Dynavax Tech Corp Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
JP4426091B2 (ja) 1997-09-05 2010-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニンを含有する水中油型エマルション
TR200002338T2 (tr) 1998-02-12 2002-06-21 Immune Complex Corporation Stratejik olarak yenilenmiş hepatit B çekirdek proteinler.
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1666060A1 (en) 1998-10-16 2006-06-07 Glaxosmithkline Biologicals S.A. Adjuvant systems and vaccines
WO2000023955A1 (en) 1998-10-21 2000-04-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Virus-like particles for the induction of autoantibodies
PT1119630E (pt) 1998-11-05 2006-05-31 Powderject Vaccines Inc Construcoes de acido nucleico para imunizacao genetica
CN100534529C (zh) 1998-11-30 2009-09-02 希托斯生物技术股份公司 抗原的有序分子呈递，制备及使用的方法
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
JP2002542203A (ja) 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
KR20020038770A (ko) 1999-09-24 2002-05-23 장 스테판느 애쥬번트로서의 폴리옥시에틸렌 소르비탄 에스테르와옥톡시놀의 조합물의 용도 및 백신과 관련된 이의 용도
CO5200838A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
DK1268530T3 (da) 2000-04-07 2006-11-13 Univ Leeds Hepatitis B-kerneantigen-fusionsproteiner
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
AU2001266163B2 (en) 2000-06-22 2006-07-13 Celltech Pharmaceticals Limited Modification of hepatitis b core antigen
AU2001269272A1 (en) 2000-07-15 2002-01-30 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
WO2003102165A2 (en) 2002-02-21 2003-12-11 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
US20030099668A1 (en) 2001-09-14 2003-05-29 Cytos Biotechnology Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
RU2324704C2 (ru) 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
CA2492930C (en) * 2002-07-19 2013-01-08 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
ATE546156T1 (de) 2002-12-10 2012-03-15 Sanofi Pasteur Biologics Co Stabilisierte immunogene chimäre hbc-partikel
BRPI0417744B8 (pt) * 2003-12-17 2021-05-25 Wyeth Corp método para produzir um conjugado imunogênico, e,conjugado imunogênico
JP2008506683A (ja) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
WO2007026190A2 (en) 2004-07-18 2007-03-08 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
DE602006015421D1 (de) * 2006-04-13 2010-08-26 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh HER-2/neu Multipeptidimpfstoff
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
CA3120504A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
FR3058624B1 (fr) 2016-11-15 2018-12-07 L'oreal Brosse pour l'application d'un produit sur les cils et/ou les sourcils

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009132689A (ja) * 2001-01-19 2009-06-18 Cytos Biotechnology Ag 分子抗原アレイ
US20080050383A1 (en) * 2006-03-29 2008-02-28 New York University Immunotherapy for clearing pathological tau conformers

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021508673A (ja) * 2017-10-27 2021-03-11 ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ タウペプチド免疫原構築物
US11773148B2 (en) 2017-10-27 2023-10-03 United Neuroscience Tau peptide immunogen constructs
KR20200094761A (ko) * 2017-12-04 2020-08-07 시아먼 이노디엑스 바이오테크 컴퍼니 리미티드 HBsAg의 정량적 검출을 위한 키트 및 방법
KR102390761B1 (ko) 2017-12-04 2022-04-25 시아먼 이노디엑스 바이오테크 컴퍼니 리미티드 HBsAg의 정량적 검출을 위한 키트 및 방법
JP2022534406A (ja) * 2019-05-27 2022-07-29 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア タウの立体配座特異的エピトープ、それらに対する抗体、およびそれらに関連する方法
JPWO2022054795A1 (enExample) * 2020-09-08 2022-03-17
WO2022054795A1 (ja) * 2020-09-08 2022-03-17 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物
JP7687699B2 (ja) 2020-09-08 2025-06-03 国立大学法人大阪大学 リン酸化タウタンパク質を標的とする免疫原性組成物

Also Published As

Publication number Publication date
TW201436804A (zh) 2014-10-01
IN2012DN00446A (enExample) 2015-05-15
EP2459214A1 (en) 2012-06-06
CO6612199A2 (es) 2013-02-01
AR078085A1 (es) 2011-10-12
CA2768346A1 (en) 2011-02-03
RU2014112002A (ru) 2015-10-10
WO2011013034A4 (en) 2011-04-28
MX2012001194A (es) 2012-03-07
CN102596236A (zh) 2012-07-18
RU2012102701A (ru) 2013-09-10
PE20120817A1 (es) 2012-07-07
KR20120049900A (ko) 2012-05-17
NZ598356A (en) 2014-06-27
US20110177109A1 (en) 2011-07-21
AU2010277254A1 (en) 2012-02-09
RU2518291C2 (ru) 2014-06-10
AU2010277254B2 (en) 2015-05-07
CN102596236B (zh) 2015-06-24
NZ618391A (en) 2015-07-31
TWI461209B (zh) 2014-11-21
TW201106968A (en) 2011-03-01
SG177637A1 (en) 2012-03-29
KR20130127547A (ko) 2013-11-22
WO2011013034A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
TWI461209B (zh) 包含抗原tau肽之免疫原及其組合物
JP5964280B2 (ja) ＩｇＥＣＨ３ペプチドワクチン
JP5859150B2 (ja) Ｐｃｓｋ９ワクチン
HK1173376A (en) Antigenic tau peptides and uses thereof
HK1163511B (zh) Ige ch3肽疫苗

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160222